The forthcoming negotiations on the Pharmaceutical Price RegulationScheme will be tough, UK Health Health Secretary Frank Dobson has said.
He told the British Pharmaceutical Conference last week that as part of the government's commitment to modernizing health care, it will not only be seeking to contain the National Health Service drugs bill but also to re-focus attention on appropriate and effective prescribing, which will mean looking at the overall benefits as well as the costs of drug treatment.
This will require a "new and more informative approach" from the drug companies, he said. In future, the NHS will be looking for further and better particulars about the effectiveness, and cost-effectiveness, of drugs. It will also want to know how best to target the new drugs on the patients who will benefit most.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze